San Francisco, United States
Vineti, founded in 2016, is a pioneering force in the arena of cell and gene therapy supply chain management. Headquartered in the United States, the company focuses on streamlining the development of personalized therapies through its flagship product, the Personalized Therapy Management (PTM®) platform.
The company's PTM® software facilitates the synchronization of patients, healthcare providers, and manufacturing processes to ensure timely and precise delivery of therapies, specifically targeting advancements in Biotechnology and Health and Wellness.
In its Series C funding round on 13 October 2020, Vineti secured a significant $33.00M investment. This round attracted major investors, including Canaan Partners, Casdin Capital, and Threshold Ventures, among others like Cardinal Health and Novartis Pharma. The robust backing underscores confidence in Vineti’s potential to scalably manage therapies integral to modern healthcare.
